Ascendis Pharma A/S (NASDAQ:ASND) Downgraded by BidaskClub

BidaskClub downgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a buy rating to a hold rating in a report released on Monday morning, BidAskClub reports.

A number of other equities research analysts have also commented on ASND. Wedbush set a $223.00 price target on Ascendis Pharma A/S and gave the stock a buy rating in a research report on Monday, June 10th. Canaccord Genuity increased their price target on Ascendis Pharma A/S from $133.00 to $144.00 and gave the stock a buy rating in a research report on Friday, May 31st. Zacks Investment Research upgraded Ascendis Pharma A/S from a hold rating to a buy rating and set a $140.00 price target on the stock in a research report on Tuesday, March 12th. Credit Suisse Group decreased their price target on Ascendis Pharma A/S from $151.00 to $139.00 and set an outperform rating on the stock in a research report on Friday, March 29th. Finally, Evercore ISI began coverage on Ascendis Pharma A/S in a research report on Monday, March 25th. They set an outperform rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $137.22.

NASDAQ ASND opened at $108.88 on Monday. Ascendis Pharma A/S has a one year low of $53.21 and a one year high of $133.96. The stock’s 50 day simple moving average is $123.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 22.32 and a current ratio of 22.32.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 30th. The biotechnology company reported ($1.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.44). The business had revenue of $6.15 million for the quarter, compared to the consensus estimate of $0.66 million. Ascendis Pharma A/S had a negative return on equity of 34.64% and a negative net margin of 901.89%. Analysts forecast that Ascendis Pharma A/S will post -5.42 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in Ascendis Pharma A/S in the 4th quarter valued at $204,000. venBio Select Advisor LLC boosted its position in Ascendis Pharma A/S by 0.8% in the 4th quarter. venBio Select Advisor LLC now owns 1,980,000 shares of the biotechnology company’s stock valued at $124,047,000 after buying an additional 16,664 shares during the last quarter. Artisan Partners Limited Partnership boosted its position in Ascendis Pharma A/S by 208.2% in the 1st quarter. Artisan Partners Limited Partnership now owns 1,131,107 shares of the biotechnology company’s stock valued at $133,131,000 after buying an additional 764,160 shares during the last quarter. Morgan Stanley boosted its position in Ascendis Pharma A/S by 53.6% in the 3rd quarter. Morgan Stanley now owns 47,100 shares of the biotechnology company’s stock valued at $3,338,000 after buying an additional 16,434 shares during the last quarter. Finally, FMR LLC boosted its position in Ascendis Pharma A/S by 1.2% in the 4th quarter. FMR LLC now owns 4,203,246 shares of the biotechnology company’s stock valued at $263,333,000 after buying an additional 50,984 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

See Also: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.